Your English writing platform
Discover LudwigSuggestions(5)
Exact(5)
gemcitabine - nab-paclitaxel must be continued until progression; nab-paclitaxel - gemcitabine must be continued until progression; gemcitabine and nab-paclitaxel - a complete break in therapy is be allowed until disease progression.
sLV5FU2 - nab-paclitaxel must be continued until progression; nab-paclitaxel - sLV5FU2 must be continued until progression; sLV5FU2 and nab-paclitaxel - a complete break in therapy is allowed until disease progression.
If adverse events require dose interruption of: sLV5FU2 - nab-paclitaxel must be continued until progression; nab-paclitaxel - sLV5FU2 must be continued until progression; sLV5FU2 and nab-paclitaxel - a complete break in therapy is allowed until disease progression.
If adverse events require dose interruption of: gemcitabine - nab-paclitaxel must be continued until progression; nab-paclitaxel - gemcitabine must be continued until progression; gemcitabine and nab-paclitaxel - a complete break in therapy is be allowed until disease progression.
The systemic therapy will be continued until progression of disease or unacceptable toxicity, followed by salvage therapy at the discretion of the local investigator.
Similar(55)
Treatment was continued until progression of disease was observed.
Treatment was continued until progression or unacceptable toxicity.
Treatment was continued until progression, unacceptable toxicity, inter-current disease or patient's refusal to continue.
If side effects were tolerable, the treatment was continued until progression of the disease was recognised.
Primary chemotherapy was continued until progression or emergence of unacceptable toxicity.
Treatment was continued until progression of the disease (PD), development of unacceptable toxicity, patients' request, or completion of the treatment.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com